Benlystas initial U.S. market will be about 200,000 peoplewith moderate to severe systemic lupus, Barry Labinger, HumanGenomes chief commercial officer, said yesterday during aconference call. The drug will cost about $35,000 a year for anaverage patient, Labinger said during the call.